A post hoc analysis of phase 3 trial data showed no association of immunogenicity with efficacy or safety for both ranibizumab and the biosimilar SB11 in patients with neovascular age-related macular degeneration.In addition, a low incidence of antidrug antibodies was found with both drugs.